1[1]Markwardt F. The development of hirudin as an antithrombotic drug. Thrombosis Research, 1994,74( 1 ): 1 ～ 23.
2[2]Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Heamost, 1991 ;66(1 ): 141 ～ 152.
3[3]Vindigni V, Filippis VD, Zanotti G, et al. Probing the structure of hirudin from hirudinaria manillensis by limited proteolysis: isolation, characterization and thrombin-inhibitory properties of N-terminal fragments. Eur J Biochem,1994,226: 323 ～ 333.
4[5]Nowak G, Markwardt F. Hirudin in disseminated intravascular coagulation.Haemostasis, 1991,21 (Supple 1 ): 142 ～ 148.
5[6]Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res, 1989,54(5) :377 ～ 388.
6[7]Zawilska K, Zozulinska M, Turowiecka Z, et al. The effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIG) in rabbits. Thromb Res, 1993,69(3): 315 ～ 320.
7[8]Doutremepuich C, Deharo E, Guyot M, et al. Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin. Thromb Res,1989,54(5) :435 ～ 445.
8[9]Talbot MD, Ambler I, Butler KD, et al. Recombinant desulphato-hirudin (CGP39393): anticoagulant and antithrombotic properties in vivo. Thromb Hemost, 1989,61 ( 1 ): 77 ～ 80.
9[10]Bara L, Bloch MF, Sanana MM. A comparative study of recombinant hirudin and standard heparin in the Wessler modle. Thromb Res, 1992,68(2): 167～ 174.
10[11]Kaiser B, Simon A, Markwardt F. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb Haemost, 1990,63 ( 1 ) :44 ～ 47.
